#Ireland #Galway #Neurent Medical #NEUROMARK #Chronic Rhinitis

Neurent Medical Secures €62.5 Million to Enhance NEUROMARK® for Chronic Rhinitis Treatment

Neurent Medical, recognized as a leader in innovative treatments for chronic rhinitis, has successfully finalized an oversubscribed Series C financing round, amassing €62.5 million (approximately $74 million). This funding is set to propel the commercial launch of its cutting-edge NEUROMARK® treatment, designed to provide a minimally invasive solution for individuals suffering from chronic rhinitis.

This financing round, which saw significant contributions from MVM Partners and Sofinnova Partners, will facilitate not only the expansion of NEUROMARK but also further development of clinical evidence supporting its use, thereby broadening its product pipeline. Existing investors, such as EQT Life Sciences, Atlantic Bridge, Fountain Healthcare Partners, and Enterprise Ireland, also played a crucial role in this funding initiative.

Chronic rhinitis affects millions globally, characterized by ongoing symptoms like nasal congestion, a runny nose, sneezing, and postnasal drip. These persistent issues can severely undermine individuals' quality of life. The NEUROMARK® system employs proprietary Impedance Controlled Radiofrequency technology, which targets the overactive posterior nasal nerves (PNN) responsible for these detrimental symptoms. This approach not only addresses the symptoms but aims at the root cause.

Brian Shields, CEO of Neurent Medical, expressed his enthusiasm about the funding, indicating that the collaboration with MVM and Sofinnova would enhance their capabilities in achieving commercial goals and ultimately bringing NEUROMARK® to the patients and healthcare professionals who require it. "Our mission has remained consistent: to significantly improve the lives of patients while providing ENT physicians with predictable and minimally invasive solutions," noted Shields.

The Implications of Funding and Technological Advancements
With this new financial backing, Neurent Medical aims to increase access to NEUROMARK® and expand its evidence base among diverse patient populations. The treatment represents a significant advancement in the management of chronic rhinitis, which has traditionally been challenging to address effectively with available options.

Kyle Dempsey, a Partner at MVM Partners, emphasized the significant potential for NEUROMARK®, stating that the posterior nasal nerve ablation technique marks a groundbreaking shift in treatment. This state-of-the-art solution promises clinical confidence for providers through real-time feedback during procedures—a capability not commonly found in current treatment methodologies.

Cedric Moreau from Sofinnova Partners also acknowledged the necessity of innovative solutions in treating chronic rhinitis, pointing out that the condition is widespread yet often misunderstood, leading to limited effective treatments. He lauded Neurent Medical for developing a distinctive method, bolstered by increasing clinical evidence that underscores patient benefits.

Future Directions
As it continues to grow, Neurent Medical is committed to transforming the treatment landscape for chronic inflammatory sinonasal diseases. The NEUROMARK® system not only provides symptom relief but also establishes a strong safety profile with minimal downtime for patients. Operating primarily out of Galway, Ireland, with additional operations in Braintree, Massachusetts, the company is dedicated to advancing both scientific understanding and clinical acceptance within the healthcare community.

Neurent Medical's strategic plans will also focus on generating further clinical evidence and possibly widening its scope to target additional indications, reflecting its commitment to improving patient outcomes in the field of ENT healthcare.

Conclusion
With the successful closing of this Series C financing, Neurent Medical stands on the forefront of a transformative journey in chronic rhinitis treatment, promising better solutions for the millions affected worldwide. As the clinical evidence accumulates and commercial practices expand, NEUROMARK® is poised to set a new standard in effectively managing chronic rhinitis and potentially reshaping the patient's experience in sinonasal care.